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Aim: The second Diabetes, Attitudes, Wishes and Needs (DAWN2™) multinational 
cross-sectional study was aimed at generating insights to facilitate innovative efforts by 
people with diabetes (PWD), family members (FMs), and health care professionals (HCPs) to 
improve self-management and psychosocial support in diabetes. Here, the French data from 
the DAWN2™ study are described.
Methods: In France, 500 PWD (80 with type 1 diabetes [T1] and 420 with type 2 diabetes [T2]), 
120 FMs, and 288 HCPs were recruited. The questionnaires assessed the impact of diabetes on 
quality of life and mood, self-management, attitudes/beliefs, and care/support.
Results: Diabetes negatively impacted the emotional well-being of 59% of people with T1 
versus 45% of people with T2 (P0.05) and about half of FMs. A high level of distress was 
felt by about half of PWD and FMs. About half of HCPs reported assessing depression in their 
patients. Sixty-two percent of FMs considered managing diabetes to be a burden. Hypoglycemia 
was a source of concern for 64% of people with T1 and 73% of FMs of insulin users. About 
two-thirds of non-insulin-medicated people with T2 agreed to start insulin if prescribed, while 
half of HCPs preferred to delay insulin initiation. A discrepancy between HCPs’ perceptions of 
their interactions with their patients and PWD’s recollection of these interactions with regard 
to patients’ personal needs and distress was also observed.
Conclusion: While distress remains under-assessed by HCPs, the negative impact of diabetes 
on the lives of PWD and FMs clearly induces distress on both groups. These findings provide 
new understanding of barriers precluding optimal management of diabetes. Developing strategies 
to overcome these barriers is now warranted. 
Keywords: health care provision, household study, psychosocial, quality of life
Introduction
A decade ago, the Diabetes, Attitudes, Wishes and Needs (DAWN) study highlighted 
the importance of paying close attention to both the medical and psychosocial needs of 
people with diabetes (PWD). Indeed, the DAWN study reported a critical discrepancy 
between the psychosocial and educational support needs of PWD, and the care and 
support available.1 Furthermore, effective collaboration among diabetes care providers 
was defined as a key factor for improving diabetes outcomes.2
During the past decade, significant advancements have been made. Indeed, 
the International Diabetes Federation (IDF) Global Guidelines for type 2 diabetes 
underlines the importance of regularly assessing the psychosocial well-being 
(eg, depression, anxiety, diabetes-specific distress, and denial of the condition) and 
requiring training of health care professionals (HCPs) to recognize psychological 
problems.3 Along with these recommendations, the acute care model has evolved 
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toward a more patient-centered, bio-psychosocial care 
model, encompassing patients’ engagement in care, shared 
decision making, and consideration of patients’ preferences 
and environment.4 Incidentally, this represents the basis for 
the new patient-centered guidelines issued by the American 
Diabetes Association and the European Association for the 
Study of Diabetes,5 and, in France, by the Haute Autorité de 
Santé.6 Despite this progress, there are still far too many PWD 
who are not getting the care and support they need, which 
could enable them to achieve optimal health and well-being. 
Therefore, access to patient-centered chronic care, education, 
and support needed to be improved.
In response, the second DAWN (DAWN2™) study was 
designed. This multinational study was aimed at generating 
insights that can facilitate innovative efforts by PWD, their 
family members (FMs), and HCPs to improve self-manage-
ment and psychosocial support in diabetes. Consequently, 
the DAWN2™ study constitutes the first major survey with 
the aim of gathering the opinions of the FMs of PWD.7 The 
primary objective of this study was to assess and explore 
potential drivers of active and successful diabetes manage-
ment among PWD, their FMs, and HCPs. In this article, we 
examine French data from the DAWN2™ study.
Materials and methods
study design
DAWN2™ is a cross-sectional, international, interdisciplinary, 
multi-stakeholder study conducted in 17 countries from four 
continents between March and August 2012 and whose method-
ology has been published elsewhere.7 In France, the DAWN2™ 
study was compliant with the French data protection author-
ity (Commission Nationale de l’Informatique et des Libertés 
[CNIL]), ie, CNIL’s registry requirements, was conducted in 
accordance with the relevant guidelines relating to the conduct 
of noninterventional studies, and used the International Chamber 
of Commerce/European Society for Opinion and Marketing 
Research, the Council of American Survey Research Organiza-
tions, and Good Pharmacoepidemiology Practices guidelines as 
a minimum standard. Data collection was anonymous.
Participants
In France, the study sample was comprised of 500 PWD 
who were diagnosed for no less than 12 months, 120 FMs, 
and 288 HCPs. All 908 participants were recruited by a 
hybrid online and telephone methodology. To ensure a 
study population as representative as possible of the wider 
diabetes community, the methodology of PWD recruitment 
was established by stratification on quotas of age, sex, 
 socioeconomics, education level, and other demographic 
information, which were based on the IDF database. Accord-
ing to quota sampling, the PWD sample, all 18 years or older, 
were comprised of 80 type 1 PWD (T1) and 420 type 2 
PWD (T2), including 100 nonmedicated T2 (T2 nonmedi-
cated) under diet and exercise regimen only, 170 non-insulin 
medicated T2 (T2 non-insulin medicated), and 150 insulin-
medicated T2 (T2 insulin-medicated). T1 had started insulin 
treatment at diagnosis, which was established before the 
age of 30 years, and were still under insulin treatment at the 
time of the study, while T2 did not start insulin treatment 
at diagnosis, which was established at or after the age of 
30 years. Excluded PWD were those under 18 years old, those 
whose diabetes had been diagnosed for less than 12 months, 
and/or those whose diabetes was related to pregnancy.
The FMs sample comprised FMs of insulin-medicated 
and non-insulin medicated PWD (FMs insulin-medicated 
and FMs non-insulin medicated, respectively). FMs were not 
diagnosed with diabetes, were living in the same household 
with a PWD, and were involved in his/her care. Only two 
FMs were linked to the interviewed PWD; the other 118 FMs 
were not related to the interviewed PWD.
The HCP sample comprised 120 general practitioners 
(GPs); 80 specialists (Sps), mainly diabetologists, endo-
crinologists, and internists; and 48 nurses and 40 dietitians 
(NDs). All HCPs had been in practice for over a year. GPs 
and NDs personally treated at least five PWD per month, and 
Sps at least 50 PWD per month. GPs were primary care phy-
sicians and internal medicine physicians who initiated oral 
medication, while Sps were endocrinologists/diabetologists 
or GPs with subspecialty in diabetes who prescribed insulin 
among other diabetes medications. HCPs were identified 
from online panels and databases.
Assessment
Three separate survey questionnaires, one for each of the 
three diabetes stakeholder groups, were designed to permit 
comparison across respondent types where possible. All three 
questionnaires were web-based and were completed pre-
dominantly online, or via a telephone interview. These were 
conducted by professionally trained interviewers, employed 
by survey research companies based in France, themselves 
employed by Harris Interactive Inc. (Rochester, USA), the 
company globally responsible for undertaking the survey. 
The questionnaires covered a wide range of topics including 
the impact of diabetes on health and quality of life (QoL), 
care and support, self-management, involvement/role of FMs, 
as well as beliefs and attitudes. To explore these topics, the 
Patient Preference and Adherence 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
291
French data from DAWn2™ study
questionnaires incorporated items from the original DAWN 
study; new questions developed by a multi-disciplinary, mul-
tinational team; as well as standardized instruments including 
World Health Organization Quality of Life-BREF (WHO 
QOL-BREF),8 EuroQoL-5D,9 World Health Organization 
5-item Well-Being Index (WHO-5),10 the Problem Areas 
in Diabetes 5 Short Form (PAID-5-SF),11,12 the Problem 
Areas in Diabetes Distress of Family Members (PAID-5-
DFM), the Health Care Climate Questionnaire (HCC),13 
and the Summary of Diabetes Self-Care Activities Measure 
(SDSCA).14 In addition, questions integrated in the question-
naires were developed with inspiration from or were adapted 
or modified from existing validated instruments including 
the Diabetes Empowerment Scale-Short Form (DES-SF),15 
Helpfulness Active Patient Involvement-DAWN Short Form 
(HAPI-DSF),16 Patient Assessment of Chronic Illness Care 
(PACIC),17,18 Diabetes Family Behavior Checklist,19 and 
DAWN Impact of Diabetes Profile (DIDP).20 Open-ended 
questions were also used to capture anecdotal information.
statistical methods
Descriptive data, presented as means (quantitative variables) 
or percentages (categorical variables), were unweighted data 
for within country comparisons, and cluster-adjusted data for 
comparisons between France and worldwide data. Adjustment 
for clustering within countries was performed using multi-
level regression models with an unstructured correlation-type 
matrix; to allow for generalizability, data for each country were 
also weighted on age, sex, region, and education according 
to population proportions, which were provided by local 
survey advisory groups, and coming from publicly available 
 epidemiological data. Differences among respondent groups 
were tested using the chi-squared test, Kendall correlation 
coefficient, Mann–Whitney test, and Kruskal–Wallis test. 
Statistical significance was set at P0.05. Comparisons pre-
sented in the figures were made by population type: PWD, 
FMs or HCPs.
Results
PWD, FM, and hcP characteristics
PWD characteristics are shown in Table 1. For FMs, the 
mean age was 35.6 years, 43% of whom were men and 58% 
women. Non-insulin medicated PWD were more often a 
relative of FMs in the non-insulin medicated group com-
pared with the insulin-medicated group (52% versus 27%, 
P0.05). Also, 35% and 26% of FMs were a spouse/partner 
of the insulin-medicated and non-insulin medicated PWD, 
respectively. Among HCPs, GPs and Sps were mostly males 
(86% and 53%, respectively), while NDs were primarily 
females (89%). Eighty-seven percent of GPs were private 
practice-/office-based while 46% of Sps and 49% of NDs 
were hospital-based.
Diabetes profile
As shown in Table 1, at least one in four PWD had both physi-
cal and emotional associated disorders. Sleeping problems 
(ranging from 36% to 46%) and depression (ranging from 
20% to 28%) were the most commonly mentioned disorders 
according to PWD respondents. 
Among all T2, 60% used diet and exercise, 58% used pills 
or tablets to manage their diabetes, and 36% were on insulin, 
whereas 46% of T1 reported using diet and exercise and 
Table 1 Patients characteristics
T1 + T2  
n=500
T1  
n=80
T2
T2 n=420 T2 nonmedicated 
n=100
T2 non-insulin  
medicated n=170
T2 insulin-medicated 
n=150
sex
Male 55% 46% 56% 51% 58% 57%
Age (years)
18–39 10% 38% 5% 16% 1% 3%
40–59 48% 53% 47% 60% 39% 48%
60 42% 10% 48% 24% 61% 49%
Mean BMi (kg/m²) 28.9 24.6 29.7 28.5 31.2 28.7
Associated disorders
Physical 21% 17% 21% 18% 24% 21%
emotional 18% 18% 19% 22% 19% 15%
Both physical and emotional 30% 34% 30% 31% 25% 35%
no other disorder 30% 31% 30% 29% 32% 29%
Notes: Physical associated disorders included stroke, open wound on the foot that did not heal without medical care, entire or partial foot/leg amputation, kidneys not 
working properly, eyesight damage, nerve damage, problems with sexual functioning, heart disease, and heart attack. emotional associated disorders included depression and 
sleeping problems. Both physical disorders and emotional disorders concerns patients displaying only disorders from the corresponding categories.
Abbreviations: BMi, body mass index; T1, type 1 diabetes; T2, type 2 diabetes.
Patient Preference and Adherence 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
292
reach et al
15% took pills or tablets. Ten percent of PWD treated their 
diabetes with alternative medicine (ie, herbal, acupuncture, 
or homeopathy) and 7% with other injectable medications.
GPs and Sps estimated that 45% and 31% of their patients 
had glycated hemoglobin levels 7%, respectively.
Qol
The impact of diabetes on several aspects of the QoL of 
PWD and FMs, assessed by DIDP, is presented in Figure 1. 
Diabetes had a negative impact on the QoL of PWD, mainly 
of T1. Thirty-seven percent of T1 and 41% of T2 presented 
with a WHO-5 score suggesting depressive mood and 14% 
of T1 and T2 with likely depression. The main domains of 
altered QoL in PWD were physical health, emotional well-
being, and leisure activities. The majority of T1 (78%) and 
T2 (67%) reported that diabetes had “slightly to very nega-
tive impact” on their physical health. The negative impact of 
diabetes on emotional well-being was greater in T1 than in T2 
(59% versus 45%, respectively, P0.05). Leisure activities 
were also more affected in T1 than in T2 (58% versus 42%, 
respectively, P0.05). Consistently, 44% of PWD felt a high 
level of distress as measured by PAID-5 scale. 
DIDP showed that diabetes also had an impact on the QoL 
of FMs. Half of FMs reported a negative impact of diabetes 
on their own emotional well-being (Figure 1). Similarly 
to what PWD reported, diabetes affected leisure activities 
in 35% and 15% of FMs insulin-medicated and FMs non-
insulin medicated, respectively. Data from the PAID-5-DFM 
scale indicated that worrying about the future and possible 
complications was a “serious or somewhat serious” problem 
for 33% and 53% of FMs non-insulin medicated and FMs 
insulin medicated, respectively (P0.05). Consistent with 
this data, 59% of FMs insulin-medicated and 65% of FMs 
non-insulin medicated considered that managing the diabetes 
of the person they live with was a moderate to very large 
burden. However, 47% of FMs reported through DIDP that 
helping a PWD had a positive impact on at least one aspect 
of their life. Indeed, respectively, 64% and 63% of FMs 
insulin medicated and FMs non-insulin medicated agreed 
that they had learned to take better care of their own health. 
Moreover, 70% and 59% of FMs insulin-medicated and FMs 
non-insulin medicated, respectively, declared that they had 
found good ways to help the person they live with by taking 
care of his/her diabetes.
Attitude and beliefs
Overall, attitudes about diabetes were largely shared by 
PWD and FMs: 86% of T1 and 89% of T2 agreed that 
complications can be avoided if the condition is care-
fully managed, and, respectively, 89% and 81% of FM 
insulin-medicated and FM non-insulin medicated had the 
same perception about the relationship between diabetes 
management and complications. Across all groups, most 
PWD were willing to follow their HCP’s recommenda-
tions. Sixty-six percent of T2 non-insulin medicated and 
57% of T2 nonmedicated said they were willing to start 
glucagon-like peptide-1 analogs, and 72% of T2 non-
insulin medicated and 61% of T2 nonmedicated said they 
were willing to start insulin if prescribed. Conversely, 
GPs and Sps preferred to delay the prescription of insulin 
100%
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Physical health Relationships Leisure activities Work or studies Emotional well-
being
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Figure 1 impact of diabetes on quality of life.
Notes: The impact of diabetes was assessed by the DAWN Impact of Diabetes Profile questionnaire. *Indicates statistical significance between subgroups, which was set 
at P0.05.
Abbreviations: DAWn, Diabetes, Attitudes, Wishes and needs; FM non-ins-med, family member of non-insulin-medicated people with diabetes; FM ins-med, family 
member of insulin-medicated people with diabetes; T1, type 1 diabetes; T2, type 2 diabetes.
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(56% and 41%, respectively) and glucagon-like peptide-1 
analogs (37% and 15%, respectively) until it becomes 
absolutely necessary.
Hypoglycemia was a source of concern not only for T1, 
but also for FMs insulin-medicated. Accordingly, 64% of T1 
and 73% of FMs insulin-medicated worried about the risk of 
night and day hypoglycemic events. Concurrently, 73% of 
T1 and 42% of T2 insulin-medicated experienced symptoms 
of hypoglycemia several times a month or as often as once 
a week (P0.05), with both groups reporting an average of 
two severe low-blood-sugar episodes in the past 12 months. 
In T2 non-insulin medicated, 22% reported symptoms of 
hypoglycemia at least once a week or several times a month 
with an average of 0.7 severe low-blood-sugar episodes in 
the past 12 months. Incidentally, lowering the hypoglycemia 
risk was one of the improvements in diabetes medication 
that 73% of GPs and 85% of Sps would find most helpful to 
achieve better patient outcomes.
Active self-management
DES-SF showed that T2 were more reluctant than T1 to ask 
others for support or to even communicate how others could 
best support them in managing their diabetes (74% versus 
58%, P0.05). Consistently, T1 were more likely than T2 
to have someone other than a HCP involved in helping them 
manage their diabetes (80% versus 65%, P0.05). HAPI-DSF 
showed that 23% of GPs, 33% of Sps, and 45% of NDs agreed 
that it is very helpful when patients let HCPs know how they 
can best support them in managing their diabetes. 
Concerning adherence to HCP recommendations, 
SDSCA showed that PWD reported that they took all of their 
HCP recommended medications on average about 6 days per 
week, followed a healthy eating plan at least 4 days per week, 
but exercised less than 4 days per week. As shown in Figure 
2, PWD, FMs, and HCPs all agreed that eating healthily, 
exercising, and maintaining a healthy weight were the key 
areas where substantial improvement is needed.
care and support
Almost all PWD had seen a HCP for their diabetes in the past 
12 months. The proportion of T2 visiting a GP was higher 
compared with T1 (87% versus 69%, P0.05). Conversely, 
the proportion of T1 visiting a Sp was higher compared to T2 
(74% versus 43%, P0.05). Half of PWD considered their 
health care team to be very supportive. However, only one-
third reported that their HCP asked if they had been anxious 
or depressed whereas about half of HCPs reported assessing 
depression in their patients. The perceptions of these two 
stakeholder groups was assessed by PACIC and HCC. This 
disparity between HCPs’ perceptions of their interactions 
with their patients and the patients’ recollection of these 
interactions is further illustrated in Figure 3. About 10% of 
PWD reported that their HCPs “always” asked them if they 
had problems with their medications and subsequent effects, 
encouraged them to ask questions, and listened to how they 
would like to do things. On the other hand, on average, 
approximately 25% of GPs, one-third of Sps, and more than 
half of NDs reported to “always” ask these questions.
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Figure 2 self-care improvement: PWD’s, FMs’, and hcPs’ perspectives.
Note: *Indicates statistical significance between subgroups, which was set at P0.05. comparisons were made by population type: PWD, FMs or hcPs.
Abbreviations: FMs, family members; FM ins-med, family members of insulin-medicated PWD; FM non-ins-med, family member of non-insulin-medicated PWD; hcPs, health 
care professionals; PcPs/gPs, primary care physicians/general practitioners; PWD, people with diabetes; T1, type 1 diabetes; T2 ins-med, insulin-medicated people with type 
2 diabetes; T2 non-ins-med, non-insulin-medicated people with type 2 diabetes; T2 non-med, nonmedicated people with type 2 diabetes.
Patient Preference and Adherence 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
294
reach et al
100%
T1 T2
SpecialistsPCPs/GPs
Nurses/dietitians
75%
50%
25%
*
*
*
*
*
*
*
*
*
*
*
*
*
*
0%
Asked how
diabetes affects
life
Asked about
problems with
medications
Encouraged
questions
Helped making
plans to achieve
goals
Helped get
support 
from others
Encouraged
group or class
attendance
Asked for ideas
when making
diabetes care
plans
Listened to how
they would like
to do things
PW
D
 a
nd
 H
C
Ps
 re
po
rt
in
g 
th
at
 th
ei
r
he
al
th
 c
ar
e 
te
am
/th
ey
 a
lw
ay
s 
en
ga
ge
 
in
 e
ac
h 
be
ha
vi
or
 (%
)
Figure 3 health team support behaviors: PWD’s and hcPs’ perspectives.
Notes: The stakeholders’ perspective was assessed by the Patient Assessment of Chronic Illness Care and the Health Care Climate Questionnaire questionnaires. *Indicates 
statistical significance between subgroups, which was set at P0.05. comparisons were made by population type: PWD on one hand, hcPs on the other hand.
Abbreviations: hcPs, health care professionals; PcPs/gPs, primary care physicians/general practitioners; PWD, people with diabetes; T1, type 1 diabetes; T2, type 2 
diabetes.
Discussion
The findings from this study of 908 participants underline the 
impact diabetes has on PWD, and FMs. It also confirms that 
although depression is a common disorder in PWD, this emo-
tional disorder remains under-assessed by HCPs. Altogether, 
these results suggest that providing support is necessary, not 
only for PWD but also for their FMs, to achieve successful 
management of diabetes.
To have a holistic perspective of the effect of diabetes, its 
impact on several aspects of the life of the PWD was evalu-
ated in this study. The most negatively impacted aspects of 
QoL were physical health, emotional well-being, and leisure 
activities, with physical health and leisure activities being 
reported as more impacted in France than for the global 
international set of PWD (65.1% versus 61.2%, and 40.5% 
versus 36.1%, respectively).21 This negative impact could be 
attributed to the fear of hypoglycemia, which was a major 
concern notably in T1. Hence, this study further indicates 
that T1 felt a greater negative effect from diabetic conditions 
on emotional well-being and leisure activities than did T2. 
This data is consistent with that of previous studies22 which 
showed that the QoL of PWD was reduced and that the mag-
nitude of negative impact differed between T1 and T2.23,24
In line with the impairment of QoL, approximatively 
halh of PWD experienced a high level of distress accord-
ing to PAID-5 scale, in France, versus 41% for the global 
 international set of PWD.21 The WHO-5 scale showed that 
14.0% of PWD for France versus 14.8%  for the global 
international set of PWD21 suffered from likely depression in 
this study, which is consistent with the depression prevalence 
reported in the literature.25 Despite this apparent problem, 
HCPs seemed reluctant to manage the psychological prob-
lems of PWD as only one-third of PWD reported that their 
HCPs discussed their distress. This point was previously 
addressed in the original DAWN study, which showed that 
HCPs felt unable to manage their patients’ psychological 
needs.1 Interestingly, when compared with patient reports, 
a higher proportion of HCPs reported that they “always” 
ask psychological questions. This apparent misreporting 
by HCPs may be an effect of denial, in the framework of 
the effect of denial on HCPs’ clinical inertia.26 Considering 
that depression had been associated with poor glycemic 
control,27 complications from diabetes,28 and increased 
mortality,29 the under-assessment of emotional distress and 
depression reported in this study suggests that strategies 
need to be implemented to provide adequate psychological 
management and support for patients suffering from these 
problems. Indeed, as previously underlined in the original 
DAWN study,1 HCPs should receive appropriate training 
to better identify among their patients those suffering from 
depression and subsequently refer them to psychiatrists for 
confirmation of the diagnosis.
FMs of PWD reported a negative impact on various 
life dimensions due to the diabetes of the person they care 
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for or live with. Diabetes clearly affected their emotional 
well-being (49.0% versus 44.5% for France versus the 
global international set of PWD, assessed by DIDP),20 
which could be related to the concerns that FMs expressed 
about the future of the person with diabetes or the risk of 
hypoglycemia as well as the burden they felt from caring 
for the person with diabetes. These findings are consistent 
with those of previous studies, showing that diabetes affects 
both the persons with diabetes and their relatives.30,31 This 
highlights that the psychological problems of FMs should be 
addressed to support them in the management of the diabetes 
of the person they care for or live with. An important point 
of this study was the assessment of the positive impact of 
diabetes on FMs (45.9% versus 34.5% for France versus 
global, assessed by DIDP).20 The majority of FMs found that 
helping the person with diabetes had a positive impact on at 
least one aspect of their own life; however, the proportion 
of FMs reporting a moderate to very large burden in helping 
the person they live with manage their diabetes radically 
differs between France, displaying the higher percentage, 
and the global international set of FMs (60.0% versus 
33.7% for France).20 This concurrent reporting of negative 
and positive impacts of diabetes in this study suggests that 
FMs have to deal with complex feelings about living with 
a person with diabetes.
Efforts are also required to overcome the resistance to 
insulin therapy. Indeed, in this study, HCPs preferred to 
delay the insulin initiation until it was absolutely necessary. 
By contrast, the vast majority of T2 non-insulin medicated 
were willing to start insulin if prescribed, possibly because 
insulin therapy is viewed with a distant future perspec-
tive. However, these findings differ from those of previous 
studies reporting greater insulin-therapy reluctance among 
PWD.32,33 This willingness to start insulin if necessary may 
be linked to the understanding of most patients and FMs 
that an appropriate management plan may help in avoiding 
complications. It alternatively may be linked to a change of 
appreciation by patients and FMs concerning the real burden 
of insulin therapy.
This study also points out the discrepancy between 
HCPs’ perceptions of their interactions with patients and 
the patients’ recollection of these interactions. While few 
PWD felt the need to participate in the medical decision-
making process, about one-quarter of HCPs reported to have 
involved their patients in this process. Although we cannot 
link specific PWD with their own HCP, our results suggest a 
lack of communication between the patient and the provider 
in general. This assumption is supported by other studies 
indicating differences in the concepts and perspectives of 
PWD and HCPs.34 Given that improved patient–provider 
communication may enhance diabetes self-care and diabetes 
outcomes,35 our study identifies a key driver of successfully 
managed diabetes. 
There are limitations to this study. First, we acknowledge 
that contributing PWD, and FMs of PWD, may exhibit higher 
levels of adherence and satisfaction than the population from 
which they were drawn. Unfortunately, detailed information 
on PWD who did not participate in the study cannot be pro-
vided due to the hybrid recruitment methodology. Likewise, 
HCPs who participated in the DAWN2™ study may declare 
themselves more attentive to their patients’ feelings that the 
average real-life standard care. This could explain the high 
discrepancy observed between both stakeholders’ interac-
tion recollection. Second, as most FMs and patients were 
not linked, we do not know whether the attitudes of PWD 
and their FMs toward diabetes are related to each other. 
Thirdly, the statistical model of this descriptive study was 
not powerful enough as confounders were not controlled for, 
and, as data were unweighted, the results of this study and 
the subsequent discussion may not be fully representative of 
the national global population.
Conclusion
In conclusion, the DAWN2™ study has provided new under-
standing of the barriers precluding the optimal management 
of diabetes. These barriers notably include the distress and 
burden felt by the PWD and by FMs. Despite this negative 
impact of diabetes on emotional status, this study indicates 
that HCPs experience difficulty in handling the psychological 
problems of PWD, or find that they do not have adequate 
resources/training to effectively manage these problems 
or actively encourage patients to manage their condition. 
Consequently, innovative strategies must now be developed 
to overcome these barriers and achieve successful diabetes 
management with improved outcomes.
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